2025 Q3 -tulosraportti
42 päivää sitten32 min
61,20 DKK/osake
Viimeisin osinko
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
177
Myynti
Määrä
1 554
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 624 | 624 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 624 | 624 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 7.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 9.5. | |
| 2024 Q4 -tulosraportti | 28.2. | |
| 2024 Q3 -tulosraportti | 7.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenA small recap on Gubra and my own expectations. A strange fluctuation today after good news. But it does give some peace of mind that Niels Vrang is stepping in and taking a small extra portion. Now both owners - Niels Vrang and Jelsing - as well as the new CEO have bought in during the late autumn months. Positive. Furthermore, one must actually say that Gubra has been consolidated as an investment lately. If Boehringer had dropped their triple-agonist, the share price would have plummeted, perhaps all the way down to 320 - which for some reason it has touched several times on really bad days. Instead, Boehringer has taken the candidate into phase 2. So, for this medication, things are calm and smooth sailing for now. Partnership agreement with Swedish Camurus in Lund. Positive. Now we are awaiting phase 1b data for Gubra's/AbbVie's amylin. Data is expected in January. But perhaps it will come before the end of the year. And it will, of course, be exciting if they reveal the effect. (We know that amylin is well tolerated in humans). I noted that AbbVie, during their conference call in the autumn, said they would conduct another study towards the end of 2026 in obese individuals. I didn't understand if this should be perceived as yet another 1b study - or if it should be seen as a phase 2 study. The American journalist who asked the question did not follow up. But "time is of the essence" and as a shareholder, one would, of course, like to see the next milestone come to payment (if it comes to payment at all upon transition to phase 2). But here there is uncertainty. My conspiratorial brain can't help but wonder... But okay, the long-acting amylin has not become less hot after the acquisition race for Metsera! So here, too, things are calm. UCN2 is going into clinic at the beginning of the new year. That will be big news once they start. But of course, much bigger news when the first data on tolerability becomes public in a few months. The expectation is that Gubra will be really strong if there are good results. Quite far in front, so there is also a prospect that UCN2 could become bigger than GuBamy! AbbVie would surely have liked to have UCN2 in their pocket (cheaply) when they traded GuBamy in the spring. But won't they be at the top of the dance card if UCN2 goes smoothly through all of phase 1? (However, I personally can't help but hope that Novo, having learned from the Metsera blunder, gets their act together). That makes autumn 2026 and spring 2027 truly exciting months. In the meantime, I think Gubra will come up with new candidates for the pipeline, which will be developed with the billions they have in the bank..... There was something about women's diseases, which is a medically neglected area with great potential. I hope they take it seriously. (I own Gubra shares).
·11 t sitten · MuokattuNice summary and good reflections. I quite agree and that's why I have bought in relatively heavily into Gubra. There are simply so many ways this can go well, and also quite a few where it can go even really well. It can also go badly, but I find it hard to see that it could reasonably go completely wrong. I also miss more of the private equity funds buying in. Where are the pension funds? Initially, they will probably buy from Vrang and Jelsing, but they are guaranteed not to go below 50% combined, as they would then lose the majority regarding acquisitions etc. So at some point, they will have to go out and get hold of the free shares. And then mine will become quite expensive if they want them. https://www.inderes.dk/companies/Gubra/ownership
·1 päivä sittenInsider buy: Took it as a sign and bought at price 472 Will be exciting to see·12 t sittenI would have preferred to see it fall to 450-460 to then supplement before the big increase "maybe" comes :)
·27 min sittenYou'll have to settle for the increase from now on and up :)- ·2 päivää sittenAnother partnership secured. That is excellent news.
·1 päivä sittenPartnerships are rarely positive for Gubra's stock price. I don't have an explanation. - ·11.12.Here are first links to 2 interesting posts about BI 3034701. The first one here, is for the protocol itself for the trial, i.e. Phase-I If one clicks further on “Record History” and then further on the last date 2025-11-18, one sees that the last update in the database is on Nov. 18-21. https://clinicaltrials.gov/study/NCT06352437
·8.12.Things are moving fast today 😎🚀·12.12.Yes, if one were a bit conspiratorially inclined, one could easily get the thought that these large daily fluctuations were precisely intended to trigger stop-loss orders. Well, but I had actually expected it to go down and test it again, so that's why I had no stop-loss set. In fact, I don't use stop-loss that often. I rely more on my TA analysis being correct. These knock outs where the price quickly drops sharply happen occasionally and are something algorithm trading systems use to tune their parameters. And they are often triggered just before the upward movement begins. Therefore, it's easy to be left at the bottom of the hill, as the cyclists say...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
42 päivää sitten32 min
61,20 DKK/osake
Viimeisin osinko
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenA small recap on Gubra and my own expectations. A strange fluctuation today after good news. But it does give some peace of mind that Niels Vrang is stepping in and taking a small extra portion. Now both owners - Niels Vrang and Jelsing - as well as the new CEO have bought in during the late autumn months. Positive. Furthermore, one must actually say that Gubra has been consolidated as an investment lately. If Boehringer had dropped their triple-agonist, the share price would have plummeted, perhaps all the way down to 320 - which for some reason it has touched several times on really bad days. Instead, Boehringer has taken the candidate into phase 2. So, for this medication, things are calm and smooth sailing for now. Partnership agreement with Swedish Camurus in Lund. Positive. Now we are awaiting phase 1b data for Gubra's/AbbVie's amylin. Data is expected in January. But perhaps it will come before the end of the year. And it will, of course, be exciting if they reveal the effect. (We know that amylin is well tolerated in humans). I noted that AbbVie, during their conference call in the autumn, said they would conduct another study towards the end of 2026 in obese individuals. I didn't understand if this should be perceived as yet another 1b study - or if it should be seen as a phase 2 study. The American journalist who asked the question did not follow up. But "time is of the essence" and as a shareholder, one would, of course, like to see the next milestone come to payment (if it comes to payment at all upon transition to phase 2). But here there is uncertainty. My conspiratorial brain can't help but wonder... But okay, the long-acting amylin has not become less hot after the acquisition race for Metsera! So here, too, things are calm. UCN2 is going into clinic at the beginning of the new year. That will be big news once they start. But of course, much bigger news when the first data on tolerability becomes public in a few months. The expectation is that Gubra will be really strong if there are good results. Quite far in front, so there is also a prospect that UCN2 could become bigger than GuBamy! AbbVie would surely have liked to have UCN2 in their pocket (cheaply) when they traded GuBamy in the spring. But won't they be at the top of the dance card if UCN2 goes smoothly through all of phase 1? (However, I personally can't help but hope that Novo, having learned from the Metsera blunder, gets their act together). That makes autumn 2026 and spring 2027 truly exciting months. In the meantime, I think Gubra will come up with new candidates for the pipeline, which will be developed with the billions they have in the bank..... There was something about women's diseases, which is a medically neglected area with great potential. I hope they take it seriously. (I own Gubra shares).·11 t sitten · MuokattuNice summary and good reflections. I quite agree and that's why I have bought in relatively heavily into Gubra. There are simply so many ways this can go well, and also quite a few where it can go even really well. It can also go badly, but I find it hard to see that it could reasonably go completely wrong. I also miss more of the private equity funds buying in. Where are the pension funds? Initially, they will probably buy from Vrang and Jelsing, but they are guaranteed not to go below 50% combined, as they would then lose the majority regarding acquisitions etc. So at some point, they will have to go out and get hold of the free shares. And then mine will become quite expensive if they want them. https://www.inderes.dk/companies/Gubra/ownership
- ·1 päivä sittenInsider buy: Took it as a sign and bought at price 472 Will be exciting to see·12 t sittenI would have preferred to see it fall to 450-460 to then supplement before the big increase "maybe" comes :)·27 min sittenYou'll have to settle for the increase from now on and up :)
- ·2 päivää sittenAnother partnership secured. That is excellent news.·1 päivä sittenPartnerships are rarely positive for Gubra's stock price. I don't have an explanation.
- ·11.12.Here are first links to 2 interesting posts about BI 3034701. The first one here, is for the protocol itself for the trial, i.e. Phase-I If one clicks further on “Record History” and then further on the last date 2025-11-18, one sees that the last update in the database is on Nov. 18-21. https://clinicaltrials.gov/study/NCT06352437
- ·8.12.Things are moving fast today 😎🚀·12.12.Yes, if one were a bit conspiratorially inclined, one could easily get the thought that these large daily fluctuations were precisely intended to trigger stop-loss orders. Well, but I had actually expected it to go down and test it again, so that's why I had no stop-loss set. In fact, I don't use stop-loss that often. I rely more on my TA analysis being correct. These knock outs where the price quickly drops sharply happen occasionally and are something algorithm trading systems use to tune their parameters. And they are often triggered just before the upward movement begins. Therefore, it's easy to be left at the bottom of the hill, as the cyclists say...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
177
Myynti
Määrä
1 554
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 624 | 624 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 624 | 624 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 7.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 9.5. | |
| 2024 Q4 -tulosraportti | 28.2. | |
| 2024 Q3 -tulosraportti | 7.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
42 päivää sitten32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 7.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 9.5. | |
| 2024 Q4 -tulosraportti | 28.2. | |
| 2024 Q3 -tulosraportti | 7.11.2024 |
Datan lähde: FactSet, Quartr
61,20 DKK/osake
Viimeisin osinko
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenA small recap on Gubra and my own expectations. A strange fluctuation today after good news. But it does give some peace of mind that Niels Vrang is stepping in and taking a small extra portion. Now both owners - Niels Vrang and Jelsing - as well as the new CEO have bought in during the late autumn months. Positive. Furthermore, one must actually say that Gubra has been consolidated as an investment lately. If Boehringer had dropped their triple-agonist, the share price would have plummeted, perhaps all the way down to 320 - which for some reason it has touched several times on really bad days. Instead, Boehringer has taken the candidate into phase 2. So, for this medication, things are calm and smooth sailing for now. Partnership agreement with Swedish Camurus in Lund. Positive. Now we are awaiting phase 1b data for Gubra's/AbbVie's amylin. Data is expected in January. But perhaps it will come before the end of the year. And it will, of course, be exciting if they reveal the effect. (We know that amylin is well tolerated in humans). I noted that AbbVie, during their conference call in the autumn, said they would conduct another study towards the end of 2026 in obese individuals. I didn't understand if this should be perceived as yet another 1b study - or if it should be seen as a phase 2 study. The American journalist who asked the question did not follow up. But "time is of the essence" and as a shareholder, one would, of course, like to see the next milestone come to payment (if it comes to payment at all upon transition to phase 2). But here there is uncertainty. My conspiratorial brain can't help but wonder... But okay, the long-acting amylin has not become less hot after the acquisition race for Metsera! So here, too, things are calm. UCN2 is going into clinic at the beginning of the new year. That will be big news once they start. But of course, much bigger news when the first data on tolerability becomes public in a few months. The expectation is that Gubra will be really strong if there are good results. Quite far in front, so there is also a prospect that UCN2 could become bigger than GuBamy! AbbVie would surely have liked to have UCN2 in their pocket (cheaply) when they traded GuBamy in the spring. But won't they be at the top of the dance card if UCN2 goes smoothly through all of phase 1? (However, I personally can't help but hope that Novo, having learned from the Metsera blunder, gets their act together). That makes autumn 2026 and spring 2027 truly exciting months. In the meantime, I think Gubra will come up with new candidates for the pipeline, which will be developed with the billions they have in the bank..... There was something about women's diseases, which is a medically neglected area with great potential. I hope they take it seriously. (I own Gubra shares).·11 t sitten · MuokattuNice summary and good reflections. I quite agree and that's why I have bought in relatively heavily into Gubra. There are simply so many ways this can go well, and also quite a few where it can go even really well. It can also go badly, but I find it hard to see that it could reasonably go completely wrong. I also miss more of the private equity funds buying in. Where are the pension funds? Initially, they will probably buy from Vrang and Jelsing, but they are guaranteed not to go below 50% combined, as they would then lose the majority regarding acquisitions etc. So at some point, they will have to go out and get hold of the free shares. And then mine will become quite expensive if they want them. https://www.inderes.dk/companies/Gubra/ownership
- ·1 päivä sittenInsider buy: Took it as a sign and bought at price 472 Will be exciting to see·12 t sittenI would have preferred to see it fall to 450-460 to then supplement before the big increase "maybe" comes :)·27 min sittenYou'll have to settle for the increase from now on and up :)
- ·2 päivää sittenAnother partnership secured. That is excellent news.·1 päivä sittenPartnerships are rarely positive for Gubra's stock price. I don't have an explanation.
- ·11.12.Here are first links to 2 interesting posts about BI 3034701. The first one here, is for the protocol itself for the trial, i.e. Phase-I If one clicks further on “Record History” and then further on the last date 2025-11-18, one sees that the last update in the database is on Nov. 18-21. https://clinicaltrials.gov/study/NCT06352437
- ·8.12.Things are moving fast today 😎🚀·12.12.Yes, if one were a bit conspiratorially inclined, one could easily get the thought that these large daily fluctuations were precisely intended to trigger stop-loss orders. Well, but I had actually expected it to go down and test it again, so that's why I had no stop-loss set. In fact, I don't use stop-loss that often. I rely more on my TA analysis being correct. These knock outs where the price quickly drops sharply happen occasionally and are something algorithm trading systems use to tune their parameters. And they are often triggered just before the upward movement begins. Therefore, it's easy to be left at the bottom of the hill, as the cyclists say...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
177
Myynti
Määrä
1 554
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 624 | 624 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 624 | 624 | 0 | 0 |